Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes
NCT02081326Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2015
- Primary completion
- Jul 2029
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bcg vaccine in type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA) and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Change in HbA1c values at 5 years. Started Jun 2015; status: active, not recruiting.
02
Drugs
bcg vaccine
03
Conditions
type 1 diabetes mellitus (T1D)latent autoimmune diabetes in adults (LADA)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT02081326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02081326.